It has been suggested24 that the better prognosis of the HER2‐low breast cancer may be related to the higher expression of Luminal related genes in the HER2‐low breast cancer, as this improves the response of the HER2‐low breast cancer to endocrine therapy. This evidence concerns the gene ERBB2 and breast carcinoma.